[1]杜 娟.亮丙瑞林治疗子宫内膜异位症伴不孕的应用[J].医学信息,2020,33(13):43-45.[doi:10.3969/j.issn.1006-1959.2020.13.012]
　DU Juan.Application of Leuprolide in the Treatment of Endometriosis with Infertility[J].Medical Information,2020,33(13):43-45.[doi:10.3969/j.issn.1006-1959.2020.13.012]
点击复制

亮丙瑞林治疗子宫内膜异位症伴不孕的应用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年13期
页码:
43-45
栏目:
综述
出版日期:
2020-07-01

文章信息/Info

Title:
Application of Leuprolide in the Treatment of Endometriosis with Infertility
文章编号:
1006-1959（2020）13-0043-03
作者:
杜 娟
（天津蓟州区人民医院妇科，天津 301900）
Author(s):
DU Juan
(Gynecology Department,Tianjin Jizhou District People’s Hospital,Tianjin 301900,China)
关键词:
子宫内膜异位症; 不孕症; 亮丙瑞林
Keywords:
Endometriosis; Infertility; Leuprolide
分类号:
R711.6；R711.71
DOI:
10.3969/j.issn.1006-1959.2020.13.012
文献标志码:
A
摘要:
子宫内膜异位症（EMT）是内膜细胞种植于子宫以外位置而引起的慢性、炎症性疾病，在育龄妇女中发病率高达10%~15%，其临床症状主要为慢性盆腔疼痛、性交痛、痛经等，并引起继发性不孕，病情反复难以治愈，现已成为临床研究重点。亮丙瑞林（LA）是由视丘下部产生的黄体生成激素释放激素（LHEH）的高活性衍生物，其化学结构与天然促性腺激素释放激素相似，但亲和力比天然促性腺激素释放激素高，生物学活性较高，可直接作用于脑垂体，抑制垂体促性腺激素释放，促进子宫内膜萎缩，现被临床广泛应用于子宫疾病治疗中。本文就LA治疗EMT伴不孕的作用机制及药物安全性进行综述，以期为该病的临床用药提供参考依据。
Abstract:
Endometriosis (EMT) is a chronic, inflammatory disease caused by endometrial cells planted outside the uterus. The incidence rate in women of childbearing age is as high as 10% to 15%, and its clinical symptoms are mainly chronic pelvic pain and sexual intercourse. Pain, dysmenorrhea, etc., and cause secondary infertility, the disease is difficult to cure repeatedly, has now become the focus of clinical research. Leuprolide (LA) is a highly active derivative of the luteinizing hormone-releasing hormone (LHEH) produced by the hypothalamus. Its chemical structure is similar to that of natural gonadotropin-releasing hormone, but its affinity is higher than that of natural gonadotropin-releasing hormone,high biological activity, can directly act on the pituitary gland, inhibit the release of pituitary gonadotropin, promote endometrial atrophy, and is now widely used in clinical treatment of uterine diseases. This article reviews the mechanism of action of LA in the treatment of EMT with infertility and drug safety, with a view to providing a reference for the clinical use of the disease.

参考文献/References:

[1]李云莉,张秦,杨正勤,等.孕三烯酮联合炔雌醇环丙孕酮治疗子宫内膜异位症的疗效及作用机制[J].发育医学电子杂志,2020,8(2):163-167.[2]张彬彬,刘晶晶,李丹,等.腹腔镜联合小金胶囊及亮丙瑞林治疗子宫内膜异位症临床评价[J].中国药业,2020,29(6):128-131.[3]钟沛文,张四友,关宝星.腹腔镜手术联合曲普瑞林治疗轻度子宫内膜异位症并不孕临床观察[J].中国药业,2019,28(22):41-43.[4]濮莲芳,金友存,蔡钱根,等.重度子宫内膜异位症术后左炔诺孕酮宫内缓释系统联合GnRH-a辅助治疗效果[J].中国计划生育学杂志,2020,28(1):22-25.[5]周梦,张薏.散结镇痛胶囊联合GnRH-a治疗子宫内膜异位症术后气滞血瘀证患者的疗效分析[J].浙江临床医学,2020,22(1):38-40.[6]张利平,李娜.雌激素阈值理论指导下的子宫内膜异位症术后巩固治疗研究[J].实用临床医药杂志,2019,23(5):93-95,99.[7]刘海琳,熊志芳.GnRH-a联合腹腔镜手术治疗子宫内膜异位症合并不孕的临床疗效[J].医学综述,2020,26(1):204-208.[8]宋菁华,鲁桦,张军,等.腹腔镜手术联合促性腺激素释放激素激动剂治疗内异症的临床研究[J].中华妇产科杂志,2013,48(8):584-588.[9]王丽萍,金晓芳,王晓红.亮丙瑞林联合米非司酮治疗子宫内膜异位症的临床观察[J].中国基层医药,2019,26(19):2395-2399.[10]Bulletti C,Coccia ME,Battistoni S,et al.Endomelriosis and infertility[J].Journal of Assisted Reproduction and Genetics,2010,27(8):441-447.[11]王霞,秦明丽,刘芳,等.亮丙瑞林注射剂联合佳蓉片治疗子宫内膜异位症伴不孕的临床研究[J].中国临床药理学杂志,2017,33(12):1120-1122,1126.[12]郁平,姬小凡,王敏,等.腹腔镜手术联合亮丙瑞林、戊酸雌二醇治疗子宫内膜异位症效果及对腹腔液血管内皮生长因子、糖类抗原125水平影响[J].临床误诊误治,2020,33(2):46-51.[13]Roberto M,Maria CA,Montagnani MM,et al.GnRH and GnRH receptors in the pathophysiology of the human female reproductive system[J].Human Reproduction Update,2016,22(3):358-381. [14]Sparic R,Mirkovic L,Malvasi A,et al.Epidemiology of Uterine Myomas:A Review[J].International Journal of Fertility&Sterility,2016,9(4):424-435.[15]李向尊,李红萍.小金片联合亮丙瑞林治疗子宫内膜异位症的临床研究[J].现代药物与临床,2020,35(4):773-777.[16]张慧君,沈志娟,覃小敏,等.经阴道直肠阴道隔子宫内膜异位症病灶部分切除术联合屈螺酮决雌醇长期维持治疗的效果观察[J].中国性科学,2019,28(12):66-70.[17]王琦,邵欣,刘小强.亮丙瑞林辅助腹腔镜治疗子宫内膜异位症临床疗效评价[J].中国药业,2018,27(9):23-25.[18]董建新,左振伟.腹腔镜联合亮丙瑞林微球蛋白对子宫内膜异位症患者TNF-α及MMP-9的影响[J].中国煤炭工业医学杂志,2017,20(6):636-639.[19]徐建锋,陈翠平,马艳娜,等.醋酸亮丙瑞林治疗子宫内膜异位症效果和对氧化应激及炎症反应的影响[J].解放军医药杂志,2018,30(5):105-108.[20]李燕.腹腔镜术后用亮丙瑞林治疗卵巢型子宫内膜异位症临床观察[J].山西医药杂志,2016,45(22):2679-2681.[21]王西,张龙华,陈瑜.腹腔镜手术联合亮丙瑞林治疗子宫内膜异位症对患者卵巢功能及受孕率影响[J].解放军预防医学杂志,2019,37(10):127-128.[22]段丽红,董辉,马朝阳.亮丙瑞林联合腹腔镜手术治疗子宫内膜异位症的临床疗效观察[J].医药论坛杂志,2018,39(5):124-125.[23]徐士儒,许健,陈聪,等.GnRH拮抗剂方案对黄体中期子宫内膜免疫细胞数量的影响[J].生殖医学杂志,2019,28(12):1463-1468.[24]朱国平,张甦.子宫内膜异位症伴不孕患者腹腔镜术后不同治疗方法对妊娠率的影响[J].中国性科学,2015(6):86-88.[25]朱晓华,张晓兰,赵霞,等.不同药物治疗子宫内膜异位症合并不孕的疗效对比[J].中国妇幼健康研究,2019,30(1):85-89.[26]黄淑娴,曹欢欢,程雪菊.腹腔镜下卵巢子宫内膜异位症囊肿剥除术前应用亮丙瑞林微球的效果及对卵巢储备功能的影响[J].临床和实验医学杂志,2017,16(22):2232-2235.[27]沈栗帆,何艳,季菲,等.醋酸亮丙瑞林对子宫内膜异位症内分泌水平及骨密度的影响[J].新疆医科大学学报,2017,40(2):170-173.[28]杨柳,许莉莉.腹腔镜手术联合亮丙瑞林皮下注射治疗对中重度子宫内膜异位症患者生育指数、血清粘结合蛋白多糖-1的影响[J].中国生育健康杂志,2019,30(5):456-459.[29]皮洁,洛若愚,贾胜楠,等.不同药物治疗腹腔镜术后子宫内膜异位合并不孕的效果观察[J].中国妇幼保健,2016,31(3):639-641.

相似文献/References:

[1]黄震洲,张龙梅,荣宝山.黄海波教授三紫汤诊治子宫性不孕经验浅谈[J].医学信息,2018,31(10):143.[doi:10.3969/j.issn.1006-1959.2018.10.048]
　HUANG Zhen-zhou,ZHANG Long-mei,RONG Bao-shan.Professor Huang Haibo's Experience in Treating Uterus Infertility with Sanzi Decoction[J].Medical Information,2018,31(13):143.[doi:10.3969/j.issn.1006-1959.2018.10.048]
[2]郭晓钰.子宫内膜异位症性不孕的中西医治疗[J].医学信息,2022,35(09):58.[doi:10.3969/j.issn.1006-1959.2022.09.014]
　GUO Xiao-yu.Chinese and Western Medicine Treatment of Endometriosis Infertility[J].Medical Information,2022,35(13):58.[doi:10.3969/j.issn.1006-1959.2022.09.014]
[3]刘秀娟,马艳华,马月巧,等.腹腔镜联合罗氏内异方治疗中、重度子宫内膜异位症 相关不孕的疗效观察[J].医学信息,2018,31(13):77.[doi:10.3969/j.issn.1006-1959.2018.13.022]
　LIU Xiu-juan,MA Yan-hua,MA Yue-qiao,et al.Observation on the Curative Effect of Laparoscopic Combined with Luo’s Internal Prescription for Severe Endometriosis Related Infertility[J].Medical Information,2018,31(13):77.[doi:10.3969/j.issn.1006-1959.2018.13.022]
[4]刘秀娟,刘 辉.子宫内膜异位症相关性不孕的诊断及治疗研究[J].医学信息,2018,31(14):35.[doi:10.3969/j.issn.1006-1959.2018.14.012]
　LIU Xiu-juan,LIU Hui.Diagnosis and Treatment of Endometriosis Related Infertility[J].Medical Information,2018,31(13):35.[doi:10.3969/j.issn.1006-1959.2018.14.012]
[5]孔俊沣,钟 雯,刘 嵩,等.MRI对卵巢子宫内膜异位囊肿的诊断价值[J].医学信息,2022,35(11):165.[doi:10.3969/j.issn.1006-1959.2022.11.044]
　KONG Jun-feng,ZHONG Wen,LIU Song,et al.The Diagnostic Value of MRI in Ovarian Endometriotic Cyst[J].Medical Information,2022,35(13):165.[doi:10.3969/j.issn.1006-1959.2022.11.044]
[6]李跃飞,郑晶晶,于聪祥.干细胞标记物Musashi-1与子宫内膜异位症关系的研究进展[J].医学信息,2018,31(23):48.[doi:10.3969/j.issn.1006-1959.2018.23.014]
　LI Yue-fei,ZHENG Jing-jing,YU Cong-xiang.Advances in Research on the Relationship between Cell Marker Musashi-1 and Endometriosis[J].Medical Information,2018,31(13):48.[doi:10.3969/j.issn.1006-1959.2018.23.014]
[7]邬素珍,许焕英,陈 玉,等.子宫内膜异位症痛经患者体质分布规律研究[J].医学信息,2019,32(15):80.[doi:10.3969/j.issn.1006-1959.2019.15.025]
　WU Su-zhen,XU Huan-ying,CHEN Yu,et al.Study on the Distribution Law of Dysmenorrhea in Patients with Endometriosis[J].Medical Information,2019,32(13):80.[doi:10.3969/j.issn.1006-1959.2019.15.025]
[8]陈 玉,邬素珍,朱巧玲.子宫内膜异位症痛经患者情志状况的临床观察[J].医学信息,2020,33(01):106.[doi:10.3969/j.issn.1006-1959.2020.01.032]
　CHEN Yu,WU Su-zhen,ZHU Qiao-ling.Clinical Observation of Emotional Status in Patients with Endometriosis Dysmenorrhea[J].Medical Information,2020,33(13):106.[doi:10.3969/j.issn.1006-1959.2020.01.032]
[9]李国馨.妇科因素所致慢性盆腔痛的研究[J].医学信息,2020,33(05):59.[doi:10.3969/j.issn.1006-1959.2020.05.018]
　LI Guo-xin.Study on Chronic Pelvic Pain Caused by Gynecological Factors[J].Medical Information,2020,33(13):59.[doi:10.3969/j.issn.1006-1959.2020.05.018]
[10]李昌秀,黄 婷.直肠子宫内膜异位症1例报道[J].医学信息,2020,33(17):191.[doi:10.3969/j.issn.1006-1959.2020.17.060]

更新日期/Last Update: 1900-01-01